AGR2 and familial pancreatic carcinoma: The silencing of AGR2 in the MPanc-96 pancreatic cancer cell line using siRNA and shRNA significantly increased the effectiveness of gemcitabine treatments in 98% of neoplastic cells in comparison with cells that had a high AGR2 expression level [46].